GB2324534B - Composition for delivery of nucleic acid to a cell - Google Patents

Composition for delivery of nucleic acid to a cell

Info

Publication number
GB2324534B
GB2324534B GB9814355A GB9814355A GB2324534B GB 2324534 B GB2324534 B GB 2324534B GB 9814355 A GB9814355 A GB 9814355A GB 9814355 A GB9814355 A GB 9814355A GB 2324534 B GB2324534 B GB 2324534B
Authority
GB
United Kingdom
Prior art keywords
delivery
cell
composition
nucleic acid
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9814355A
Other versions
GB2324534A (en
GB9814355D0 (en
Inventor
Martin Charles Garnett
Fiona Caroline Maclaughlin
Stanley Stewart Davis
Fabio Bignotti
Paolo Ferruti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9600272.0A external-priority patent/GB9600272D0/en
Application filed by Danbiosyst UK Ltd, West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical Danbiosyst UK Ltd
Priority to GB9814355A priority Critical patent/GB2324534B/en
Publication of GB9814355D0 publication Critical patent/GB9814355D0/en
Publication of GB2324534A publication Critical patent/GB2324534A/en
Application granted granted Critical
Publication of GB2324534B publication Critical patent/GB2324534B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB9814355A 1996-01-06 1997-01-06 Composition for delivery of nucleic acid to a cell Expired - Fee Related GB2324534B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9814355A GB2324534B (en) 1996-01-06 1997-01-06 Composition for delivery of nucleic acid to a cell

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9600272.0A GB9600272D0 (en) 1996-01-06 1996-01-06 Polymers
GB9814355A GB2324534B (en) 1996-01-06 1997-01-06 Composition for delivery of nucleic acid to a cell
PCT/GB1997/000022 WO1997025067A2 (en) 1996-01-06 1997-01-06 Polymers

Publications (3)

Publication Number Publication Date
GB9814355D0 GB9814355D0 (en) 1998-09-02
GB2324534A GB2324534A (en) 1998-10-28
GB2324534B true GB2324534B (en) 2000-05-10

Family

ID=26308436

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9814355A Expired - Fee Related GB2324534B (en) 1996-01-06 1997-01-06 Composition for delivery of nucleic acid to a cell

Country Status (1)

Country Link
GB (1) GB2324534B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865723A (en) * 1972-03-21 1975-02-11 Zambon Spa Method to form stable complexes of polyanions occurring in biological liquids
US4093677A (en) * 1975-06-10 1978-06-06 Paolo Ferruti Macromolecular materials suitable for forming antithrombogenic prosthesis and artificial organs and process for preparing same
EP0451954A2 (en) * 1990-04-10 1991-10-16 Huntsman Corporation Polyether amides and process for the preparation thereof
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
EP0672677A2 (en) * 1994-03-14 1995-09-20 Hoechst Aktiengesellschaft Polyamide-oligonucleotide derivatives, their production and use
WO1995034595A1 (en) * 1994-06-15 1995-12-21 Biomolecular Research Institute Ltd. Antiviral dendrimers
WO1996002655A1 (en) * 1994-07-13 1996-02-01 Rhone-Poulenc Rorer S.A. Nucleic acid containing composition, preparation and uses of same
WO1996015778A1 (en) * 1994-11-18 1996-05-30 Supratek Pharma, Inc. Polynucleotide compositions
EP0727233A2 (en) * 1995-02-02 1996-08-21 Rainer H. Frey Biocompatible material and method of manufacture and use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865723A (en) * 1972-03-21 1975-02-11 Zambon Spa Method to form stable complexes of polyanions occurring in biological liquids
US4093677A (en) * 1975-06-10 1978-06-06 Paolo Ferruti Macromolecular materials suitable for forming antithrombogenic prosthesis and artificial organs and process for preparing same
EP0451954A2 (en) * 1990-04-10 1991-10-16 Huntsman Corporation Polyether amides and process for the preparation thereof
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
EP0672677A2 (en) * 1994-03-14 1995-09-20 Hoechst Aktiengesellschaft Polyamide-oligonucleotide derivatives, their production and use
WO1995034595A1 (en) * 1994-06-15 1995-12-21 Biomolecular Research Institute Ltd. Antiviral dendrimers
WO1996002655A1 (en) * 1994-07-13 1996-02-01 Rhone-Poulenc Rorer S.A. Nucleic acid containing composition, preparation and uses of same
WO1996015778A1 (en) * 1994-11-18 1996-05-30 Supratek Pharma, Inc. Polynucleotide compositions
EP0727233A2 (en) * 1995-02-02 1996-08-21 Rainer H. Frey Biocompatible material and method of manufacture and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry, Vol. 6, no. 6, 1 November 1995, pages 639-643, A V Kabanov et al *
Experimental Biology 95, Part I, April 9-13, 1995 & FASEB J.9(3), 1995. A312, page 1807, Bielinska *
Macromolecules (1991), Vol. 24, pages 3747-3752, E Ranucci et al *
Macromolecules (1994), Vol. 27, pages 7171-7178 F Bignotti et al *
Macromolecules (1995), Vol. 28(24), pages 8259-8271, A G Shard et al *

Also Published As

Publication number Publication date
GB2324534A (en) 1998-10-28
GB9814355D0 (en) 1998-09-02

Similar Documents

Publication Publication Date Title
AU3133097A (en) Chitosan related compositions for delivery of nucleic acids into a cell
AU5743996A (en) Compositions and methods for nucleic acid delivery to the lu ng
ZA9510138B (en) Cosmetic compositions containing betullnic acid
AU4065397A (en) Stable compositions for nucleic acid amplification and sequencing
EP0769552A4 (en) Antisense nucleic acid compound
EP0735093A4 (en) Binder for cell and composition for electrode and cell prepared therefrom
AU2001259846A1 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
EP0690716A4 (en) OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH
AU2602297A (en) Thickened acid composition
NZ324642A (en) Composition for delivery of nucleic acids
HUP0001937A3 (en) Compounds, preparation and use for transferring nucleic acids into cells
HU9800329D0 (en) Nucleic acid construct for the cell cycle regulated expression of structural genes
HUP0004375A3 (en) Composition containing azelaic acid
AU6229498A (en) Composition for gene introduction into cell
AUPM874394A0 (en) Improvements to brick walls
AU5659596A (en) Feed composition containing poly-gamma-glutamic acid
GB9515356D0 (en) Improvements in or relating to delivery of nucleic acid
EP0713648A3 (en) Leavening acid composition
AU8505898A (en) Nucleic acid compositions and methods of introducing nucleic acids into cells
AU7724198A (en) Use of genes encoding xylan synthase to modify plant cell wall composition
GB2324534B (en) Composition for delivery of nucleic acid to a cell
HUP0001061A3 (en) Naphthylsulfonic acid derivatives and pharmaceutical compositions containing them
PL342165A1 (en) Antienzymic composition containing ethylenediamino disuscinic acid
AU4959497A (en) Pharmaceutical composition containing bismuth-polyacrylic acid compounds
GB9626986D0 (en) Pharmaceutical compositions for delivery of nucleic acid to cell nucleus

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20050106